Literature DB >> 3517560

Effect of alpha-glycohydrolase inhibitors (Bay m1099 and Bay o1248) on sucrose metabolism in normal men.

M Cauderay, L Tappy, E Temler, E Jéquier, I Hillebrand, J P Felber.   

Abstract

The inhibitory effect of N- beta-(4-ethoxycarbonylphenoxy-ethyl-1-desoxynojirimycin (BAY o1248) and of N-hydroxyethyl-1-desoxynojirimycin (BAY o1099) was studied in normal men. Nine healthy volunteers (weight range of 82% to 117% of their ideal body weight) ingested a 50 g sucrose load together with placebo, 50 mg BAY m1099, or 10 mg BAY of o1248. Their substrate oxidation rate was measured by continuous indirect calorimetry during four hours. The plasma glucose and plasma insulin peaks were both significantly blunted and the late fall of glycemia reduced. Mean plasma glucose, fructose, and insulin were reduced by both drugs during the first two hours following the sucrose load and led to a decrease of the suprabasal glucose oxidation (oxidation above baseline) during the first two hours of the test. However, the total suprabasal glucose oxidation during the four hours of the test was not significantly different from that of the control. Breath hydrogen, as an index of malabsorption, was shown to increase with both 50 mg BAY m1099 and 10 mg BAY o1248, starting from the third hour. These findings are consistent with a significant delay of sucrose absorption induced by these new alpha-glycohydrolase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3517560     DOI: 10.1016/0026-0495(86)90140-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

1.  The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics.

Authors:  K F Federlin; L Mehlburger; I Hillebrand; H Laube
Journal:  Acta Diabetol Lat       Date:  1987 Jul-Sep

2.  Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.

Authors:  G Heinz; M Komjati; A Korn; W Waldhäusl
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Inhibition of sucrose- and starch-induced glycaemic and hormonal responses by the alpha-glucosidase inhibitor emiglitate (BAY o 1248) in healthy volunteers.

Authors:  B Lembcke; U R Fölsch; W Gatzemeier; B Lücke; R Ebert; E Siegel; W Creutzfeldt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.

Authors:  Sonia A Tucci; Emma J Boyland; Jason Cg Halford
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-10       Impact factor: 3.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.